Stock takes hit: Biohaven’s pivotal bipolar drug trial fails

Biohaven's pipeline drug BHV-7000 has failed to meet the primary endpoint in its Phase II/III trial for bipolar disorder, resulting in a 13.77% drop in the company’s stock price. The trial, which involved 256 patients across 32 sites, found that BHV-7000 did not achieve statistical significance on the Young Mania Rating Scale (YMRS). Despite the setback, the drug was deemed safe and well-tolerated, with no serious adverse events reported.

Biohaven has not yet confirmed whether it will continue developing BHV-7000 for bipolar disorder. However, the drug is still being evaluated for other conditions, including major depressive disorder (MDD) and epilepsy, with results expected in late 2025 and early 2026.

BHV-7000 was acquired through Biohaven’s 2022 buyout of Channel Biosciences, and Pfizer later acquired all remaining shares of Biohaven for $11.6 billion.

In another announcement, Biohaven's candidate BHV-1300 achieved an 80% reduction in IgG levels in a Phase I study.

14-03-2025

• Pharma GMP
• Food GMP
• Clinical Research
• Medical Device
• Environmental Health and Safety
• Healthcare
• Nutrition